Cadence Capital Management Lowers stake in Amgen (AMGN)

Amgen (AMGN) : Cadence Capital Management reduced its stake in Amgen by 4.07% during the most recent quarter end. The investment management company now holds a total of 80,878 shares of Amgen which is valued at $14,026,672 after selling 3,433 shares in Amgen , the firm said in a disclosure report filed with the SEC on Aug 3, 2016.Amgen makes up approximately 1.02% of Cadence Capital Management’s portfolio.

Other Hedge Funds, Including , Amg National Trust Bank boosted its stake in AMGN in the latest quarter, The investment management firm added 4,533 additional shares and now holds a total of 8,735 shares of Amgen which is valued at $1,514,911. Amgen makes up approx 0.13% of Amg National Trust Bank’s portfolio.Proficio Capital Partners boosted its stake in AMGN in the latest quarter, The investment management firm added 86 additional shares and now holds a total of 266 shares of Amgen which is valued at $45,760. Amgen makes up approx 0.03% of Proficio Capital Partners’s portfolio.Murphy Capital Management Inc reduced its stake in AMGN by selling 2,341 shares or 17.42% in the most recent quarter. The Hedge Fund company now holds 11,100 shares of AMGN which is valued at $1,812,075. Amgen makes up approx 0.27% of Murphy Capital Management Inc’s portfolio.Nikko Asset Management Americas reduced its stake in AMGN by selling 1,000 shares or 19.23% in the most recent quarter. The Hedge Fund company now holds 4,200 shares of AMGN which is valued at $685,650. Amgen makes up approx 0.06% of Nikko Asset Management Americas’s portfolio.Burns J W Co Incny boosted its stake in AMGN in the latest quarter, The investment management firm added 1,111 additional shares and now holds a total of 5,270 shares of Amgen which is valued at $858,641. Amgen makes up approx 0.25% of Burns J W Co Incny’s portfolio.

Amgen closed down -1.32 points or -0.76% at $172.34 with 27,06,525 shares getting traded on Monday. Post opening the session at $173.31, the shares hit an intraday low of $171.83 and an intraday high of $174.16 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.

Investors should note that on Jul 22, 2016, Amgen announced a cash dividend of $1.0000. The company’s management has announced Aug 15, 2016 as the ex-dividend date and fixed the record date on Aug 17, 2016. The payable date has been fixed on Sep 8, 2016.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.